LUNG Stock Analysis: Buy, Sell, or Hold?
LUNG - Pulmonx Corporation Common Stock
$1.46
-0.08 (-5.19%)
▼
5d:
-1.35%
30d:
+2.1%
90d:
+6.57%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 29, 2026
14d
Get Alerted When LUNG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LUNG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LUNG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LUNG is currently trading at $1.46, which is considered slightly high relative to its 30-day fair value range of $1.28 to $1.49.
Technical Outlook: Technically, LUNG is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: LUNG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+132.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LUNG is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: LUNG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+132.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.28 -
$1.49
Company Quality Score
57/100
(HOLD)
Options IV Signal
56th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
72.9%
All Signals
- NEUTRAL: Options fairly priced (IV 56th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 132.9% below Wall St target ($3.40)
Trading Range Analysis
30-Day Trading Range
$1.28 -
$1.49
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.26
(17.5%)
Support & Resistance Levels
Support Level
$1.45
Resistance Level
$1.72
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.40
Wall Street Target
$3.40
(+132.9%)
Revenue Growth (YoY)
-8.7%
Profit Margin
-60.1%
Share & Embed Analysis
Last updated: July 14, 2026 3:58 AM ET
Data refreshes hourly during market hours. Next update: 4:58 AM
Data refreshes hourly during market hours. Next update: 4:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LUNG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Geoffrey Beran Rose
SELL
7732 shares
2026-03-02
Glendon E French III
SELL
67813 shares
2026-03-02
Srikanth Radhakrishnan
SELL
10483 shares
2026-03-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$74 | 65 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 57 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 62 BUY |
